Project to Revolutionise Biosensors for Point of Care Diagnostics

Expertise spanning Photonic Crystals to Proteomics is allowing the P3SENS consortium to develop technology that can satisfy the sensitivity, easy-of-use and cost requirements of an emergency-medicine diagnostic device. Cerebrovascular Disease, more commonly called "Stroke", is challenging to identify and is a condition for which rapid diagnosis greatly influences efficacy of treatment.

In 2007 the World Health Organisation estimated that 15 million people suffer Stroke worldwide each year, with 5 million dying from the conditions and another 5 million being left with a permanent disability, in Europe alone there are 650,000 Stroke deaths each year. Cerebrovascular Disease is currently the most common life threatening neurological event, and the leading cause of serious, long term disability. The early diagnosis and treatment of Stroke is desirable in order to prevent subsequent vascular events which increase the likelihood of permanent disability or death.

Neurological conditions are notoriously difficult to diagnose, relying on the interpretation of physical symptoms and subsequent brain imaging before positive identification of a condition is possible. The ability to rapidly detect the biochemical markers present within a patient’s blood as an aid to diagnosis is an attractive proposition, expected to significantly improve a patients chances of survival and subsequent quality of life.

The P3SENS consortium has been formed to develop a biochemical detection device suitable for use in emergency-medicine, whether diagnosis is required in an ambulance, emergency room or as part of a rapid laboratory test in a hospital environment – it is anticipate that the combination of highly sensitive Photonic Crystals, a panel of clinically proven Bio-Recognition Elements and low-cost production technology will result in a novel biosensor system which can make a real difference to Stroke patients worldwide.

The multidisciplinary approach to the P3SENS project is reflected by the consortium membership led by Multitel asbl in Belgium and including The Research Institute for Technical Physics and Materials Science (MFA) in Hungary, VTT Technical Research Centre of Finland (VTT), The University of Geneva in Switzerland, The University of Glasgow in the United Kingdom, Bayer Technology Services GmbH in Germany, and Stratophase Ltd in the United Kingdom.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.